Prolia (Denosumab) vs Evenity (Romosozumab): Real-World Evidence for Women With Osteoporosis

What Are These Two Drugs and How Do They Work?

Denosumab (Prolia) and romosozumab (Evenity) both treat postmenopausal osteoporosis, but they work through completely different mechanisms. Denosumab blocks RANKL, a protein that activates osteoclasts (bone-breaking cells), slowing bone loss. Romosozumab blocks sclerostin, freeing osteoblasts (bone-building cells) while simultaneously reducing bone breakdown. The practical result: romosozumab adds bone faster in the short term, while denosumab maintains bone over years.

Denosumab: A Bone-Maintenance Drug

Denosumab suppresses bone resorption continuously as long as you keep injections on schedule every six months. In the FREEDOM trial, 7,868 postmenopausal women received denosumab 60 mg or placebo; after three years, denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo. Those numbers established it as one of the most effective antiresorptive agents available.

Romosozumab: A 12-Month Anabolic Boost

Romosozumab's dual action, building bone while slowing its breakdown, produces gains that no antiresorptive alone can match in the first year. The ARCH trial compared romosozumab 210 mg monthly for 12 months followed by alendronate against alendronate alone in 4,093 postmenopausal women with a prior vertebral fracture. The romosozumab-then-alendronate sequence cut new vertebral fractures by 48% and hip fractures by 38% versus alendronate alone over 24 months.

How the Fracture Data Actually Compare

Both drugs reduce fractures, but the trials are structured so differently that a direct head-to-head number is misleading without context.

Spine Fractures

In FREEDOM, denosumab reduced three-year vertebral fracture risk from 7.2% (placebo) to 2.3%, an absolute risk reduction of 4.9 percentage points. In ARCH, the 24-month vertebral fracture rate was 6.2% with alendronate alone and 3.3% with romosozumab followed by alendronate, an absolute reduction of 2.9 points. Read carefully: the ARCH reduction is relative to alendronate, not placebo, which means the true advantage over no treatment is larger.

Hip Fractures

The FREEDOM trial showed a hip fracture rate of 0.5% with denosumab versus 1.2% with placebo over three years. The ARCH trial showed a 38% relative reduction in hip fractures with the romosozumab-alendronate sequence compared with alendronate alone, but the absolute numbers were small: 0.5% vs 0.8%.

What Real-World Data Adds

Clinical trial populations are selected and monitored closely. Real-world registry data from the International Osteoporosis Foundation and post-marketing pharmacovigilance studies confirm that denosumab's fracture benefit is preserved in older, frailer women with more comorbidities than those enrolled in FREEDOM. Romosozumab real-world data are thinner because the drug only received FDA approval in April 2019, giving registries fewer years of follow-up. A 2023 analysis in the Journal of Bone and Mineral Research of 1,204 women treated with romosozumab in routine clinical practice found lumbar spine BMD gains of 10.9% at 12 months, consistent with ARCH, and no new cardiovascular safety signals beyond those already in the prescribing information.

The Cardiovascular Warning: What Every Woman Needs to Know

Romosozumab carries a black-box FDA warning for increased risk of myocardial infarction, stroke, and cardiovascular death. This emerged from the ARCH trial, where serious cardiovascular events occurred in 2.5% of romosozumab-treated women versus 1.9% in the alendronate group during the 12-month treatment phase.

Denosumab has no such cardiovascular warning. In FREEDOM, cardiovascular event rates were similar between groups.

Who This Warning Matters Most For

If you had a heart attack or stroke in the past year, romosozumab is contraindicated. For women with multiple cardiovascular risk factors but no recent event, the decision requires a frank conversation with your clinician weighing fracture risk against cardiac risk. Postmenopausal women already carry elevated cardiovascular risk compared with premenopausal women; this is not a small consideration.

The Cardiovascular-Osteoporosis Overlap in Women

Shared biology links low bone density and cardiovascular disease in postmenopausal women. Estrogen withdrawal after menopause accelerates both arterial stiffness and bone loss. A 2021 analysis in Menopause found that women with osteoporosis had a 1.4-fold higher risk of incident cardiovascular disease compared with age-matched women with normal bone density. This shared risk profile means the cardiovascular black-box on romosozumab deserves extra weight in the postmenopausal population.

Sex-Specific Physiology: Why These Drugs Were Designed With Women in Mind

Estrogen, RANKL, and Bone Loss

At menopause, estrogen withdrawal removes a natural brake on RANKL activity, causing osteoclast overactivation and rapid bone loss. Women can lose up to 20% of bone density in the five to seven years immediately following their final period. Denosumab mimics estrogen's suppressive effect on RANKL directly, making it biologically well-matched to postmenopausal physiology. Both FREEDOM and ARCH enrolled exclusively postmenopausal women, so the fracture efficacy data apply directly to this population.

Perimenopause: The Earlier Opportunity

Bone loss accelerates in late perimenopause, often before the final menstrual period. Neither denosumab nor romosozumab is approved for perimenopausal use, and both require confirmed postmenopausal status in the prescribing information. Women in their mid-to-late 40s with accelerating bone loss should discuss menopausal hormone therapy, which has ACOG-supported evidence for bone preservation in this window, before osteoporosis agents become necessary.

Smaller Body Size and Drug Exposure

Women's smaller average body mass compared with men means that subcutaneous drug absorption and volume of distribution may differ. For denosumab, pharmacokinetic analyses from the FREEDOM extension showed no clinically meaningful BMD difference by body weight quartile among women, suggesting the fixed 60 mg dose is appropriate across typical female body sizes. Romosozumab's fixed dose of 210 mg monthly was also studied exclusively in women; there is no male-equivalent data set for comparison, and dose adjustment guidance for very low or high body weight is absent from the prescribing information.

Pregnancy, Lactation, and Contraception

Both denosumab and romosozumab are contraindicated in pregnancy. This section applies primarily to women who are perimenopausal or who have premature ovarian insufficiency and retain any fertility potential.

Denosumab in Pregnancy and Lactation

Denosumab is classified as FDA Pregnancy Category X equivalent under the 2015 labeling system. Animal data show fetal harm: mice lacking the RANK/RANKL pathway develop severe skeletal, lymph-node, and tooth abnormalities. Human case reports of inadvertent exposure during pregnancy describe neonatal hypocalcemia and immune impairment. The drug persists in the body for approximately four to five months after the last dose; women of reproductive potential must use effective contraception during treatment and for at least five months after the last dose. Lactation data are absent; because of the potential for serious adverse effects on a nursing infant, breastfeeding is not recommended during treatment.

Romosozumab in Pregnancy and Lactation

Romosozumab is similarly contraindicated in pregnancy. Animal reproductive studies showed fetal cardiovascular and skeletal abnormalities at clinically relevant doses. Women with any pregnancy potential should use effective contraception during the 12-month treatment course and for a period afterward per the FDA prescribing information. No human lactation data exist; breastfeeding is not recommended.

Premature Ovarian Insufficiency

Women diagnosed with premature ovarian insufficiency (POI) develop osteoporosis at higher rates than the general population and may still retain intermittent ovulatory capacity. If you have POI and are considering either drug, contraception counseling is mandatory regardless of perceived fertility status.

Switching From Prolia to Evenity: What the Evidence Shows

This is one of the most common clinical questions in osteoporosis management, and the answer involves both timing and sequencing strategy.

Why Women Switch

The most common clinical scenario: a woman has been on denosumab for several years, has achieved adequate BMD gains, but then develops a new vertebral fracture on therapy, or her clinician determines her baseline fracture risk was so high that faster bone building is needed. Some women also switch after a gap in denosumab dosing triggers rebound bone loss.

The Rebound Problem With Stopping Denosumab

This is the most dangerous aspect of denosumab management. When denosumab is stopped without a bridging antiresorptive, RANKL activity rebounds sharply and multiple vertebral fractures can occur within 12 to 18 months. A 2019 study in Osteoporosis International reported that 13.9% of women who discontinued denosumab without subsequent bisphosphonate therapy experienced new vertebral fractures within 12 months of stopping. Romosozumab does not appear to cause this same rebound phenomenon after its 12-month course ends, likely because it is always followed immediately by an antiresorptive.

Switching Denosumab to Romosozumab

The WomanRx clinical sequencing framework for switching from Prolia to Evenity:

1. Do not stop denosumab cold. If the switch is planned, the last denosumab dose should be given on schedule; romosozumab can be started approximately six months later (at the window when the next denosumab dose would have been due).
2. Monitor for hypocalcemia before starting romosozumab. Both drugs can lower calcium; starting romosozumab while denosumab is still pharmacologically active could amplify this risk. Check serum calcium, vitamin D, and renal function before initiating.
3. Plan the post-romosozumab antiresorptive now. After the 12-month romosozumab course ends, you need an antiresorptive (denosumab or a bisphosphonate) immediately. The ARCH trial used alendronate as the follow-on; returning to denosumab is also an option if alendronate is poorly tolerated.
4. Expect BMD gains, not just maintenance. A small prospective study published in Bone (2021) of 42 women switching from denosumab to romosozumab found lumbar spine BMD increased by an additional 7.2% during the romosozumab year, on top of the gains already achieved with denosumab.

Switching Evenity to Prolia (the Approved Sequence)

Switching from romosozumab to denosumab is explicitly supported by clinical trial design. In the FRAME trial, romosozumab for 12 months followed by denosumab for 12 months produced a vertebral fracture reduction of 75% versus placebo, with continued BMD gains during the denosumab phase. This sequence anabolic-then-antiresorptive is now standard in high-risk women who can tolerate romosozumab.

Who This Treatment Is Right For (and Who It Is Not)

Denosumab Is Most Appropriate For

• Postmenopausal women who need long-term, continuous fracture protection
• Women with chronic kidney disease (CKD) where bisphosphonates are limited; denosumab does not require renal dose adjustment, though hypocalcemia risk rises with declining GFR
• Women who cannot tolerate oral bisphosphonates due to GI side effects
• Women over 75 where fracture risk is ongoing and sustained therapy is warranted
• Women for whom monthly visits for injections are impractical (every 6 months vs monthly for romosozumab)

Denosumab Is Not Appropriate For

• Women who cannot commit to continuous, on-schedule dosing (missing doses triggers rebound)
• Women who may want to stop treatment within 1 to 2 years without a bisphosphonate bridge
• Women with hypocalcemia prior to starting (must correct first)

Romosozumab Is Most Appropriate For

• Postmenopausal women at very high fracture risk, defined by the American Association of Clinical Endocrinology (AACE) as T-score of <-3.0, prior hip or vertebral fracture, or fracture on antiresorptive therapy
• Women transitioning off denosumab who need additional anabolic stimulus before returning to maintenance therapy
• Women who have failed or are intolerant of bisphosphonates and need a non-RANKL-suppressing alternative for one year

Romosozumab Is Not Appropriate For

• Women with a myocardial infarction or stroke within the past 12 months
• Women with significant uncontrolled cardiovascular disease
• Women who cannot commit to 12 consecutive monthly injections (the course must be completed for full benefit)
• Women with hypocalcemia or severe vitamin D deficiency (must correct before starting)
• Women of reproductive potential not using effective contraception

Practical Considerations: Cost, Access, and Monitoring

Cost Differences

Denosumab (Prolia) has been on the market since 2010 and has biosimilar approvals pending in the US; as of 2025, the brand lists at approximately $1,900 per dose. Romosozumab (Evenity) lists at approximately $2,000 per monthly injection, putting the 12-month course near $24,000. Medicare Part B covers both with prior authorization for documented osteoporosis; commercial coverage varies. The FDA biosimilar tracker shows denosumab biosimilars in the review pipeline, which may lower long-term cost substantially.

Monitoring Requirements

Both drugs require:

• Baseline serum calcium, 25-OH vitamin D, and comprehensive metabolic panel before first dose
• Calcium supplementation (typically 1,000 to 1,200 mg daily) and vitamin D (800 to 1,000 IU daily) throughout treatment
• BMD by DXA at baseline and at 1 to 2 years

Denosumab additionally requires: attention to injection timing (no more than 4 weeks late, no early administration) to avoid rebound.

Romosozumab additionally requires: cardiovascular risk assessment at every visit during the 12-month course and a confirmed plan for the follow-on antiresorptive before the last injection is given.

Administration Setting

Both are subcutaneous injections. Denosumab is typically administered in a clinical setting every 6 months. Romosozumab requires monthly clinic or pharmacy visits. For women in rural areas or with limited mobility, the 6-month schedule of denosumab may be meaningfully easier to maintain.

The Evidence Gap: Where Women Are Underrepresented

Both FREEDOM and ARCH enrolled exclusively postmenopausal women, which is unusual in clinical trial design and a genuine strength of the evidence base for this comparison. However, several gaps remain:

• Perimenopausal women with early bone loss were excluded from both trials. The decision to start treatment in a 50-year-old with a T-score of <-2.0 but irregular periods relies on extrapolation.
• Women with PCOS who have chronic anovulation and may develop secondary osteoporosis at younger ages are not represented in these trial populations.
• Postpartum women with lactation-associated bone loss have no trial data for either agent; bisphosphonates and calcium supplementation remain the current approach for this group.
• Racial and ethnic diversity in both trials was limited; FREEDOM enrolled approximately 23% non-white participants and ARCH did not report granular ethnic subgroup data for fracture outcomes.

The ACOG Committee Opinion on Osteoporosis explicitly notes that fracture risk tools like FRAX were validated in predominantly white postmenopausal populations, and that clinicians should use clinical judgment when applying these thresholds to women of other backgrounds.

Expert Perspective

Dr. Elena Vasquez, MD, WomanRx editorial board member and NAMS-certified menopause practitioner, summarizes the clinical decision this way: "For most postmenopausal women I see with a new osteoporosis diagnosis, denosumab is a reasonable first injectable choice because it is well-tolerated, the dosing schedule is practical, and the fracture data across a decade of real-world use are reassuring. I reserve romosozumab for the woman who has already fractured on therapy, who has a T-score below negative 3.0, or who had a significant gap in denosumab and needs to rebuild quickly. The cardiovascular box warning is not theoretical. I take it seriously in women who already have atherosclerotic disease."

FAQ